Psychedelic medicine: mechanisms, evidence, and translation to practice

Over the past 15 years, interest in psychedelic therapies has grown quickly, driven largely by psilocybin and MDMA and by encouraging early findings across conditions such as depression, post-traumatic stress disorder (PTSD), substance use disorders, and distress related to life-threatening illness. At the same time, the authors note that enthusiasm has sometimes run ahead of the evidence. They highlight concerns about trial quality, compromised blinding because of the drugs’ noticeable subjective effects, safety monitoring, and whether the current treatment model can be implemented at scale. The recent FDA rejection of MDMA-assisted therapy for PTSD is presented as an example of the continuing debate about evidence standards and trial design. The review aims to synthesise the current evidence on classic serotonergic psychedelics, mainly psilocybin, and on MDMA, with a particular focus on proposed mechanisms of action and the challenges of translating findings into practice. The authors state that they will describe candidate biological and psychological mechanisms, summarise the clinical evidence base, discuss translational barriers, and identify future research priorities. They justify focusing on psilocybin and MDMA because these are the compounds most advanced in clinical development and because they share a treatment model involving limited dosing alongside psychotherapy or structured psychological support.

This is a narrative state-of-the-art review rather than an original empirical study. The authors searched PubMed for English-language articles published from January 2000 to January 2025, and supplemented database searching with forward citation tracking, reference list screening of recent systematic reviews, hand searching of specialist journals, and consultation with subject matter experts. They state that Box 1 contained the inclusion and exclusion criteria, and that they prioritised randomised controlled trials, systematic reviews, and meta-analyses while also including mechanistic and translational studies relevant to clinical application. The review is organised around two main compounds or treatment families: classic serotonergic psychedelics, principally psilocybin, and MDMA. Although the introduction notes that the term psychedelic can encompass other compounds such as ketamine and ibogaine, these are not the main focus here. The paper then moves from mechanisms of action to clinical evidence, safety, ongoing translational problems, scalability, emerging trials, and guidance. Because this is a review, the methods are mainly about literature identification and selection rather than participant recruitment or statistical analysis in the usual trial sense. For the clinical evidence sections, the authors draw on trials across several indications, especially PTSD, depressive disorders, substance use disorders, and distress related to life-threatening illness. They report effect estimates, confidence intervals, response and remission rates, and adverse event data where available, and they also refer to meta-analyses when summarising efficacy and harms. The paper repeatedly notes limitations in the underlying literature, including functional unblinding, small samples, restricted eligibility criteria, and short follow-up periods.

The review argues that the therapeutic effects of classic psychedelics and MDMA likely arise from interacting mechanisms at molecular, circuit, and psychological levels. At the molecular level, classic psychedelics act mainly through 5-HT2A receptor agonism, with hallucinogenic effects linked to biased signalling pathways. Preclinical evidence suggests effects on neuroplasticity, including increased expression of plasticity-related genes such as BDNF and mTOR-related components, enhanced dendritic growth and synaptic density, and possible metaplasticity, meaning a temporary increase in the brain’s capacity for future plastic change. Human evidence for these mechanisms is still limited. At the circuit level, the authors describe widespread changes in brain network organisation, including reduced within-network connectivity and increased between-network connectivity. They highlight altered default mode network activity, changes in cortico-striato-thalamo-cortical gating, and effects on emotional processing networks, including reduced amygdala reactivity in some studies. Behaviourally, the review reports post-acute increases in cognitive flexibility and improvements in emotional processing, such as better facial emotion recognition and greater behavioural engagement. The authors also discuss subjective experiences, especially mystical-type experiences, emotional breakthrough, psychological insight, and psychological flexibility, noting that these are associated with benefit in several studies but that their causal role is uncertain. For MDMA, the review reports a different but overlapping pattern of action. MDMA primarily promotes monoamine release, especially serotonin, and also norepinephrine and dopamine. It appears to reduce amygdala blood flow, increase amygdala-hippocampal connectivity, and support fear extinction and social reward learning, with oxytocin and serotonin transporter effects implicated. These effects are presented as potentially useful for trauma-focused psychotherapy because MDMA can reduce fear and increase trust, cooperation, and sociability. In PTSD, MDMA-assisted therapy showed positive results in the phase III trials. In MAPP1, 90 participants with severe PTSD received MDMA-assisted therapy or placebo with therapy; at 18 weeks, MDMA produced a significantly greater reduction in CAPS-5 scores by 11.9 points (95% CI 6.3 to 17.4; Cohen’s d=0.91). In MAPP2, 104 participants were randomised to MDMA or placebo with identical therapy; at six to eight weeks after the third and final drug session, MDMA again reduced CAPS-5 scores more than placebo by 8.9 points (95% CI -13.7 to -4.1; Cohen’s d=0.7; P<0.001), with remission in 46.2% versus 21.4% and better functioning on the Sheehan Disability Scale. However, 94% of MDMA recipients correctly guessed their allocation, showing marked functional unblinding. A meta-analysis across trials also favoured MDMA-assisted therapy, with Hedges’ g=-1.53 for CAPS-5 reduction, and higher rates of loss of diagnosis and remission. For depression, the review describes a consistent positive signal for psilocybin. In a waitlist-controlled trial of 24 participants with major depressive disorder, two psilocybin sessions led to a large reduction in depression severity at five weeks (Cohen’s d=2.6), with 71% response and 54% remission at four weeks after both sessions. In a larger trial of 104 participants using niacin as an active placebo, a single 25 mg dose of psilocybin produced a greater reduction in MADRS scores at six weeks than control (between-group difference -12.3), and 42% versus 11% achieved sustained antidepressant response. In a head-to-head trial against escitalopram in 59 participants, psilocybin did not significantly beat escitalopram on the primary outcome at six weeks, although several secondary outcomes favoured psilocybin and later follow-up showed better work and social functioning. In a larger trial of 233 people with treatment-resistant depression, 25 mg psilocybin outperformed 1 mg control on MADRS reduction (-6.6) and had a higher odds of response at three weeks (OR 2.9), but the effect was not sustained at 12 weeks. An open-label study in 29 participants, including some with bipolar II depression or personality disorder, found further symptom reductions with repeated dosing and no treatment-emergent mania or psychosis. Across substance use disorders, the results are more mixed but still promising. In alcohol use disorder, a multisite trial of 95 participants found that two psilocybin doses plus psychotherapy improved biomarker-confirmed abstinence and reduced heavy drinking days at 33-36 weeks, although functional unblinding was around 90%. Another trial in severe alcohol use disorder with comorbid depression found better abstinence at 12 weeks, whereas a different relapse-prevention study found no significant difference versus placebo. In tobacco use disorder, an open-label pilot study of 15 participants reported 80% abstinence at six months and 60% at long-term follow-up, though the study was small and uncontrolled. For distress related to life-threatening illness, two crossover trials in cancer populations reported improvements in depression, anxiety, quality of life, optimism, demoralisation, and hopelessness after psilocybin. One study of 51 patients found greater improvements with high-dose psilocybin than low-dose control, with persistent effects at six months. Another study found reduced anxiety and depression after psilocybin, and long-term follow-up suggested that more than 60% of surviving participants reported enduring antidepressant or anxiolytic effects 4.5 years later. The authors note that these samples were highly selected and, in one case, blinding was extremely poor. Safety findings suggest that psilocybin and MDMA are generally well tolerated in controlled settings, but adverse events are common and are often inadequately reported. For psilocybin trials, acute adverse effects included increased blood pressure, headache, nausea, dizziness, and anxiety; for MDMA-assisted therapy, common effects included sweating, chills, decreased appetite, mydriasis, nystagmus, and blurred vision. Psychological distress during dosing sessions can be intense, and some participants require pharmacological rescue, although this was uncommon. Subacute headache is common after psilocybin, and MDMA commonly causes fatigue, low mood, and irritability for several days. The authors also report rare but serious events, including delayed suicidal ideation or behaviour in some psilocybin recipients and a completed suicide in one control participant in a cancer-related distress trial. A meta-analysis found a low incidence of psychedelic-induced psychosis, but with substantial heterogeneity and low-quality evidence. Bipolar I disorder and schizophrenia are highlighted as important risk factors. Drug-drug interaction findings include possible worsening of anxiety and thought disturbance when haloperidol is combined with psilocybin, the need to stop 5-HT2A antagonists such as risperidone before treatment, and the possibility that SSRIs may be continued in some circumstances without clearly reducing psilocybin effects. For MDMA, SSRI pretreatment may blunt subjective effects, and haloperidol may shift the experience towards dysphoria. The review also stresses that adverse event reporting is highly variable: many studies did not systematically assess harms, and a substantial proportion of adverse events recorded in trial registries were not published in the main reports. The review highlights several translational and implementation issues. Functional unblinding is a central concern, prompting newer trials to use masked central raters and formal assessments of blinding integrity. The authors also note that high therapeutic contact requirements, long preparation and integration sessions, and specialised settings create scalability problems. Early approaches to improve access include shorter-acting compounds such as intranasal 5-MeO-DMT, with a recent trial of 193 participants reportedly showing sustained depression improvement and 90-minute discharge times, and group-based psilocybin delivery models in small feasibility studies. However, durability of benefit beyond 12 weeks remains unclear for most indications, mechanistic pathways are still not fully established, trial populations are often demographically narrow, and economic models remain tentative despite early health economic analyses suggesting potential long-term value.

The authors conclude that the field has produced genuinely promising evidence, especially for psilocybin in depression and MDMA-assisted therapy for PTSD, but that interpretation must remain cautious because of major methodological and implementation problems. They emphasise that the apparent clinical effects are likely supported by interacting neurobiological and psychological mechanisms, yet the precise causal chain from receptor-level action to network changes, subjective experience, and symptom improvement is still unresolved. They also argue that the distinctive treatment model, combining limited drug sessions with psychotherapy or structured support, is central to both the promise and the challenge of these treatments. Relative to earlier research, the authors present the current evidence as more mature than in the early psychedelic literature, with phase III trials and meta-analyses now available for some indications. Even so, they stress that the literature remains uneven across conditions, with the strongest support for PTSD and treatment-resistant depression, and more mixed evidence in substance use disorders and life-threatening illness. They note that some recent findings are encouraging for broader clinical translation, such as inclusion of more diverse participants, but that many studies still rely on homogeneous samples and intensive support models that may not generalise well. The authors repeatedly identify functional unblinding as a major interpretive limitation, especially in MDMA and psilocybin studies where participants can often infer assignment from acute subjective effects. They also point to short follow-up periods, restrictive eligibility criteria, inconsistent adverse event reporting, and uncertain long-term safety and durability as important gaps. In their view, these issues help explain why the FDA did not licence MDMA-assisted therapy in 2024 and why better trial design, including active placebos, blinded outcome assessment, and expectancy measurement, remains necessary. For future research and practice, the authors call for standardised adverse event assessment, more rigorous blinding strategies, better understanding of long-term outcomes, studies in more diverse and clinically representative populations, and implementation research on scalable delivery models. They also argue that practical questions about payment, training, clinical infrastructure, and culturally adaptable protocols need to be addressed before psychedelic treatments can be widely and safely integrated into healthcare systems.

The authors’ final conclusion is that psychedelic medicine is a rapidly evolving area with substantial therapeutic promise but serious translational challenges. They state that evidence-based enthusiasm is justified, but only if the field continues to address methodological weaknesses, safety monitoring, and implementation barriers. They emphasise the need for rigorous trials, standardised delivery and monitoring, and scalable models of care before these treatments can meet regulatory and healthcare-system demands.